ITUS (ITUS) Receiving Somewhat Favorable Media Coverage, Report Shows

Headlines about ITUS (NASDAQ:ITUS) have trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ITUS earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the business services provider an impact score of 47.8175644442936 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Separately, ValuEngine lowered shares of ITUS from a “hold” rating to a “sell” rating in a report on Thursday, December 7th.

Shares of ITUS (NASDAQ ITUS) traded up $0.01 during trading hours on Monday, reaching $2.56. 80,700 shares of the company’s stock were exchanged, compared to its average volume of 719,441. ITUS has a 12-month low of $0.60 and a 12-month high of $5.50. The company has a market cap of $39.22, a price-to-earnings ratio of -4.00 and a beta of -1.20.

ILLEGAL ACTIVITY WARNING: “ITUS (ITUS) Receiving Somewhat Favorable Media Coverage, Report Shows” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/25/itus-itus-receiving-somewhat-favorable-media-coverage-report-shows.html.

ITUS Company Profile

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream.

Insider Buying and Selling by Quarter for ITUS (NASDAQ:ITUS)

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.

ITUS (ITUS) Receiving Somewhat Favorable Media Coverage, Report Shows

Headlines about ITUS (NASDAQ:ITUS) have trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ITUS earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the business services provider an impact score of 47.8175644442936 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Separately, ValuEngine lowered shares of ITUS from a “hold” rating to a “sell” rating in a report on Thursday, December 7th.

Shares of ITUS (NASDAQ ITUS) traded up $0.01 during trading hours on Monday, reaching $2.56. 80,700 shares of the company’s stock were exchanged, compared to its average volume of 719,441. ITUS has a 12-month low of $0.60 and a 12-month high of $5.50. The company has a market cap of $39.22, a price-to-earnings ratio of -4.00 and a beta of -1.20.

ILLEGAL ACTIVITY WARNING: “ITUS (ITUS) Receiving Somewhat Favorable Media Coverage, Report Shows” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/25/itus-itus-receiving-somewhat-favorable-media-coverage-report-shows.html.

ITUS Company Profile

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream.

Insider Buying and Selling by Quarter for ITUS (NASDAQ:ITUS)

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit